Kymera Therapeutics, Inc.KYMRNASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
27.06%
↓ 47% below average
Average (6y)
51.43%
Historical baseline
Range
High:120.62%
Low:0.00%
Volatility
234.5%
High variability
| Period | Value |
|---|---|
| 2024 | 27.06% |
| 2023 | 15.12% |
| 2022 | 19.87% |
| 2021 | 120.62% |
| 2020 | 67.14% |
| 2019 | 110.18% |
| 2018 | 0.00% |